This week Poland asked a court to undo an order it received this spring: buy 64 million doses of a vaccine it does not want — nearly two per citizen, on top of millions already destroyed. This is not an episode about vaccines: the doses are legal and fully approved, and nothing here questions them as medicine. The dispute is about money and volumes.

It is an episode about a contract — one of the largest purchase contracts in European history — and the single line never written into it: what happens if tomorrow turns out better than the forecast. By the end of 2023, an estimated €4 billion of pandemic vaccines had gone to landfills across Europe. This page is the full blueprint of how that happens.

April 1: a Brussels court of first instance — the first ruling, not the last word — decided Poland must honour the contract in full: take ~64 million doses, pay ~€1.3 billion plus interest and costs. Romania, sued alongside, owes ~€600 million. Pfizer filed the case in late 2023; this Monday Poland appealed and asked to suspend enforcement. We predict nothing about how it ends.

Why Brussels? The contract was negotiated by the European Commission on behalf of all member states and is governed by Belgian law: one signature, twenty-seven countries bound. Poland stopped accepting deliveries in April 2022 — pandemic changed, refugee costs, monopoly-pricing accusation. The court's answer, in essence: obligations bind. Meanwhile the physical ledger: in 2022 alone Poland destroyed 14.8 million expired doses — one in nine delivered; the remaining stock was disposed of in 2024.

In 2020, Europe decided to buy vaccines as one customer instead of twenty-seven competing ones. The Commission negotiated advance purchase agreements: pooled bargaining power for the states, guaranteed demand for the producers. For a scarce product in a panicked market, one big buyer beats a bidding war — we watched the opposite design fail with gas.

The largest deal came in May 2021: 900 million doses firm, an option for 900 million more. Written at the peak of uncertainty — new variants, possible yearly boosters for everyone. Poland's slice is the 64 million from our opening. The risk split: delivery risk on the company (penalties), demand risk entirely on the states. And two things were not in the text: any mechanism to scale volumes down — call it a shrink clause — and any free right to resell or donate surplus. A forecast, with a signature under it.

By 2022 demand collapsed while deliveries kept arriving on the 2021 schedule. Poland simply stopped accepting them. A renegotiation did happen — the 2023 amendment: remaining volume cut by about a third per reporting, deliveries pushed out, a fee per cancelled dose. That is the shrink clause, written two years late — as an offer, not a right. Most states signed; Poland did not, and stayed bound by the original text. Pfizer sued Poland — and Romania, over its own undelivered doses. The court did the only thing courts do with clear text: read it out loud and enforced it.

So walk the exits. Scale down — not in the text. Resell freely — restricted. Renegotiate — a favour. What remains is the one exit no contract can block: expiry and disposal. One dose in nine that Poland received in 2022 ended in destruction; €4 billion worth ended in landfills across Europe. The incinerator became the system's relief valve.

Let's be fair to the people who built this in 2021. Firm volumes bought speed and priority in the scarcest market on Earth; producers built factories against those guarantees; the company carried real delivery risk and delivered. Paying for certainty was a defensible trade — possibly the right one.

The defect is narrower: the downside branch was never priced out loud. The contracts were confidential — lawmakers who asked got redacted copies, prices blacked out — so no public document stated what an early end to the pandemic would still cost. No scheduled review, no formula, no arbiter, no reopening date. And the strongest proof it was a design flaw, not fate: Europe already built the corrected version — EU FAB, since 2023, pays four manufacturers to keep 325 million doses a year of ever-warm capacity, activated only in an emergency. The next crisis is covered by the new design. The last one is still being settled under the old one.

Buy options. A premium buys the right to doses batch by batch; demand confirms each batch. Price: every delivered dose costs more; firm buyers outrank option holders in a scramble; someone still underwrites the factory.

Price the corridor. Min–max volumes with pre-agreed step fees — the 2023 improvisation written as a right, day one. Price: the maker prices the risk into every dose; disputes migrate into the formula; complexity costs days when days are scarce.

Pay for the factory. EU FAB scaled: retainers keep lines warm, doses ordered only in crisis. Price: idle lines paid for years; capacity is not doses; scaling to pandemic size multiplies the bill. The current design pays too: €1.9 billion across two countries, plus the landfills — and counting.

If the ruling stands, the 64 million doses will be manufactured, paid for, stored — and, in all likelihood, eventually destroyed. Every step lawful, every step following the text. Whatever you believe about pandemic decisions, notice who wrote this bill: not the virus, not the court. It was written into a purchase order in 2021, in the branch nobody filled in.

The transferable question, for every emergency contract any government signs: don't only ask what happens if things go wrong. Ask what happens if things go right — who holds the pen on that branch, and what using it will cost. If the answer is "we'll renegotiate when we get there," remember Poland: renegotiation was a favour, refusal was a lawsuit, and the relief valve was an incinerator. An emergency excuses speed. It does not excuse a blank page.